ALTERITY THERAPEUTICS LIMITED (ATH)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

ATH

ATH - ALTERITY THERAPEUTICS LIMITED

FNArena Sector : NONE
Year End: June
GICS Industry Group : Consumer Services
Debt/EBITDA: -0.01
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.01

28 Jan
2026

0.000

OPEN

$0.01

0.000

HIGH

$0.01

1,998,198

LOW

$0.01

FNARENA'S MARKET CONSENSUS FORECASTS

- No Record -

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx-0.2
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx0.0 M
Book Value Per Share xxxxxxxxxxxxxxx0.5
Net Operating Cash Flow xxxxxxxxxxxxxxx-11.5 M
Net Profit Margin xxxxxxxxxxxxxxx-

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx-43.23 %
Return on Invested Capital xxxxxxxxxxxxxxx-43.12 %
Return on Assets xxxxxxxxxxxxxxx-37.23 %
Return on Equity xxxxxxxxxxxxxxx-43.23 %
Return on Total Capital xxxxxxxxxxxxxxx-70.82 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-11.5 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxxxxx0 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx41 M
Price To Book Value xxxxxxxxxxxxxxx2.15

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx0.0 M
Capex % of Sales xxxxxxxxxxxxxxx-
Cost of Goods Sold xxxxxxxxxxxxxxx0 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx20 M
Research & Development xxxxxxxxxxxxxxx14 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

0
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

17/12/2025

1

Initiation of coverage with Speculative Buy

$0.016

60.00%

Canaccord Genuity has initiated coverage of Alterity Therapeutics with a Speculative Buy rating and target price of 1.6c.

The company is developing ATH434 for synucleinopathies such as MSA and Parkinson’s by targeting excess brain iron linked to neurodegeneration.

Two Phase II studies (87 patients total) delivered a range of positive efficacy signal, positioning ATH434 as the first iron-modulating therapy to show this breadth. Phase III MSA trial is expected to start within 12 months.

With no approved disease-specific MSA treatments, similar Phase III outcomes could drive rapid uptake and potential peak sales of US$1.5bn, in the broker's view.

The fully de-risked valuation is estimated at 4.8c.

FORECAST
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -10.00 cents.
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -20.00 cents.
Access Extra Coverage Research History >

ATH STOCK CHART

FNArena News on ATH

1
Australian Broker Call *Extra* Edition – Dec 18, 2025

Dec 18 2025 - Daily Market Reports
2
Class of 2020

Jul 09 2020 - Rudi's View